The progress in precision medicine, with Epidermal Growth Factor Receptor (EGFR) inhibitors, Anaplastic Lymphoma Kinase (ALK) inhibitors, and immune checkpoint inhibitors, has significantly improved survival and quality of life for patients with advanced lung cancer [24,33]. This evidence concerns the gene ALK and lung cancer.